Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

FDA approvals 2017

- PMLiVE

Gilead makes $11.9bn play for CAR-T specialist Kite

The agreement is due to close in this year’s fourth quarter

- PMLiVE

Kite starts EU trial of lead CAR-T therapy

Adult patients with DLBCL, PMBCL and TFL will be enrolled in the trial

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

- PMLiVE

Merck suspends two Keytruda trials after patient deaths

Investigators to look at Keytruda with Pomalyst and Revlimid

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

- PMLiVE

Gilead Sciences appoints general manager, Canada

Nordics general manager Kennet Brysting moves to take up new post

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Sanofi biologics supply VP joins Kite Pharma

Dr Jian Irish becomes senior vice president of supply chain

- PMLiVE

Making a list and checking it twice…

The promise of mobile health lies not in recording information but in promoting behaviour change

- PMLiVE

Novartis plans filing for lead CAR-T therapy early next year

Shows complete remission for 82 percent of paediatric and young adult B-cell ALL patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links